Clinuvel Pharmaceuticals (CUV AU): Portfolio Expansion Ensures Continued Profitable Growth
Clinuvel recorded double-digit revenue growth in H1FY23, backed by strong uptake of Scenesse. This year, the company launched its first...
Short Interest Movements (Q1 2023): HK, Korea, Taiwan, Australia
The Insight looks at movements in short interest across HK, Korea, Taiwan and Australia stocks over Q1 and highlights large increases/decreases in...
Clinuvel Pharmaceuticals (CUV AU): Strong Start of FY23; Pipeline Progress Enhances Conviction
Data readouts for Clinuvel’s DNA repair program on XP patients expected early next year is potentially groundbreaking as it will open an innovative...
Smartkarma Originals